“He genetically manipulates the T cells to identify, attack and kill several myeloma cells. “T-cell CAR therapies such as BB2121 have shown ave shown a high response rate even in patients with recurrent or refractory multiple myeloma, although this is not a cure,” “she” says. Since 2015, several new drugs have been approved for the treatment of multiple myeloma, including recurrent and refractory forms of disease,” Lee says. CAR-T cell therapy has proven effective in treating other blood cancers, lymphoma, and doctors are now examining whether it can also help with multiple myeloma, Dr. Lee says. T-cell attackers are two-handed antibodies that fight cancerous cells in two different ways: they target BCMA cells and T cells that are part of their own immune system,” “he” said. HDAC inhibitors kill several myeloma cells without allowing them to produce a specific protein that causes rapid cell growth. The T-cell becomes active, comes into contact with the myeloma cell and kills it: “These drugs are also known as specific biscopic antibodies that contain T cells or BITE.” Progress in genomic medicine is another positive development in the treatment of multiple myeloma,” says Dr. Lee. “Over the last 10-15 years we have made tremendous progress in the treatment of multiple myeloma, which in the 1990s had limited treatment options. It looks for proteins and then kills the cancerous cells to which it is attached.